Resumen:
Anti-thymocyte globulin in multi-refractory immune-mediated cytopenia is an effective treatment, with response rate as high as 65%. Younger patients, presenting with thrombocytopenia or neutropenia, and those with LGL and STAT3 mutations appear to be more likely responsive.